Biomedical Catalyst Feasibility Award to Tackle Drug-resistant Ovarian Cancer
News Sep 17, 2013
MISSION Therapeutics has been granted a Biomedical Catalyst Feasibility Award by the Technology Strategy Board to support the identification of DUBs required for the survival of drug-resistant ovarian cancers.
Ovarian cancer is the fifth most common cancer in women and is responsible for more deaths per year than any other cancer of the female reproductive system.
Unfortunately, development of drug resistance remains the main limitation of current chemotherapies for ovarian cancer.
Identifying novel targets and therapies tailored for treating drug-resistant ovarian cancer is thus an area of clear unmet clinical need.
Using an innovative approach, MISSION will identify novel DUB targets by exploiting the very changes in tumours that led to the development of drug resistance.
Commenting on the announcement, Dr Niall Martin, MISSION Chief Operating Officer, said: “The decision of the Technology Strategy Board to support our work shows the potential the DUB space holds for treating cancer. The funds from this Feasibility Award will be used to screen all known DUBs to find those which are suitable targets for our drug development programmes.”
The project will see MISSION identify DUB targets whose inhibition selectively kills drug-resistant ovarian tumours or re-sensitizes them to chemotherapy.
The most promising targets will enter MISSION’s pipeline for further drug discovery efforts with a view to developing new therapeutic agents for ovarian cancer.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE
Fight Against Cancer: Drug Combination Helps Kickstart the Immune SystemNews
Scientists from King's College London have found a way to boost the immune system to help it fight back against cancer.
The breakthrough involves the first ever use of a combination of chemotherapy and a drug being trialled as a treatment for neonatal jaundice, that together help kick start the body's natural defences.
Researchers Zoom in on DNA Code Being Read in CellsNews
Scientists have unveiled incredible images of how the DNA code is read and interpreted – revealing new detail about one of the fundamental processes of life. The mechanism for reading DNA and decoding it to build proteins for their needs is common to all animals and plants, and is often hijacked by cancer. The discovery of exactly how the molecular mechanism works, could open up new approaches to cancer treatment.READ MORE